SillaJen Biotherapeutics, Inc. is a biotechnology company headquartered in San Francisco, founded in 2003. The company focuses on the research, development, and manufacturing of oncolytic viruses to treat cancer. It operates in one of the largest biotech clusters in the world and handles Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management, and Accounting for clinical trials. SillaJen has a South Korean base with satellite offices in Seoul and San Francisco, CA. Their primary focus is on developing and commercializing oncolytic immunotherapy products using the SOLVETM platform, with its lead product Pexa-Vec currently in Phase 3 trials for the treatment of advanced primary liver cancer. This promising endeavor has attracted a significant $12.00M Venture Round investment from Medivate Partners on 21 March 2016. For more information, visit www.sillajen.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $12.00M | 1 |
|
21 Mar 2016 |
No recent news or press coverage available for SillaJen.
We care about your data, and we'd love to use cookies make your experience better.
